Penumbra, Inc.

NYSE:PEN

Medical - Devices

Healthcare
$320.60 -0.72%

-$2.30 today

Market cap
$12.64B
Beta
0.70
P/E (TTM)
72.6
EPS (TTM)
$4.36
52W Low $221.26High $362.41

Volume 0.21M

Average 0.50M

PEN Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Penumbra, Inc.NYSE: PEN

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income dips below year-ago levels

Q2 FY2026 net income of $34.81M fell 23.1% year over year, behind the +8.7% change in trailing-twelve-month net income. Sequentially, it rose 6.8% from the prior quarter.

Context

  • Net income amounted to 12.7% of revenue in FY2025, up 11.5 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of $188.14M (+5.9%) for the fiscal year ending Dec 2026, a slowdown from the +1168.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$34.81M+6.8% QoQ
Last fiscal yearDec 2025
$177.69M+1168.1% YoY
LTMJun 2026
$160.59M+8.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.1%+4.0%+27.1 pp
1 year+1168.1%+5.9%-1162.2 pp
3-year CAGR—+17.2%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
177.69M USD
Year-over-year change
+1168.1%
4-year CAGR
+140.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How PEN compares with its peers on the latest reported figures

  • PEN's LTM Jun 2026 net income of $160.59M is the 6th largest of the 9 companies compared; the peer median is $1.99B.
  • Its year-over-year change of +8.7% is the 5th highest of 9, against a peer median of +10.0%.
  • Net income amounts to 10.7% of revenue for PEN, versus a peer median of 14.7%.
PEN Competitors Peer median
Net Income for PEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABTAbbott LaboratoriesLTM Jun 2026$5.43B -61.2%-2.0%11.6%
MDTMedtronic plcLTM Jul 2026$5.27B +12.7%+8.5%14.0%
BSXBoston Scientific CorporationLTM Jun 2026$3.67B +34.6%+60.6%17.5%
ISRGIntuitive Surgical, Inc.LTM Sep 2026$2.97B +7.4%+28.9%25.6%
EWEdwards Lifesciences CorporationLTM Jun 2026$1B -75.8%-11.1%15.4%
PENPenumbra, Inc.LTM Jun 2026$160.59M +8.7%—10.7%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$160.12M +35.2%+19.9%9.9%
LMATLeMaitre Vascular, Inc.LTM Mar 2026$62.4M +38.2%+40.9%24.3%
ANGOAngioDynamics, Inc.LTM Feb 2026$31.39M -24.2%+8.6%10.0%
Peer median (excluding PEN) $1.99B+10.0%+14.3%14.7%

Competitors are the stored peer set for PEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income5.28M(2M)90.95M14.01M177.69M
Depreciation & Amortization16.41M24.32M27.26M23.7M17.47M
Deferred Income Tax(14.09M)1.46M(19.06M)(16.34M)21.03M
Stock-Based Compensation00046.16M59.21M
Change in Working Capital(66.71M)(121.54M)(79.08M)(23.78M)(42.72M)
Accounts Receivables(21.34M)(69.86M)(266K)26.6M(19.51M)
Inventory(51.55M)(74.63M)(67.71M)(65.66M)(26.48M)
Accounts Payables(1.57M)13.39M1.1M4.17M3.07M
Other Working Capital7.75M9.57M(12.21M)11.11M213K
Other Non-Cash Items68.61M42.1M77.27M124.72M5.97M
Operating Cash Flow9.5M(55.66M)97.33M168.48M238.66M
Capital Expenditures(21.18M)(19.3M)(15.21M)(21.18M)(63.73M)
Acquisitions (Net)2.92M0(988K)00
Purchases of Investments(126.79M)0(81.94M)(32.91M)(355.74M)
Sales of Investments123.72M74.09M82.57M130.62M14.88M
Other Investing Activities(400K)0(500K)1.1M0
Investing Cash Flow(21.74M)54.79M(16.08M)77.62M(404.59M)
Debt Repayment(1.45M)(1.75M)(1.98M)(2.28M)(2.49M)
Common Stock Issued18.37M21.55M20.41M17.17M31.82M
Common Stock Repurchased000(100.39M)0
Dividends Paid00000
Other Financing Activities(16.08M)(8.18M)(2.23M)(1.52M)(2.8M)
Financing Cash Flow836K11.62M16.2M(87.01M)26.53M
Effect of Forex Changes1.11M(272K)168K(2.18M)1.89M
Net Change in Cash(10.29M)10.48M97.63M156.92M(137.51M)
Free Cash Flow(11.68M)(74.96M)82.12M147.3M174.93M

Penumbra, Inc.

NYSE:PEN

Intrinsic Alpha fair value

Locked

Current Price

$320.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.